Mycobacterium tuberculosis (Mtb) is an obligate aerobe that is capable of long-term persistence under conditions of low oxygen tension. Analysis of the Mtb genome predicts the existence of a branched aerobic respiratory chain terminating in a cytochrome bd system and a cytochrome aa3 system. Both chains can be initiated with type II NADH:menaquinone oxidoreductase. We present a detailed biochemical characterization of the aerobic respiratory chains from Mtb and show that phenothiazine analogs specifically inhibit NADH:menaquinone oxidoreductase activity. The emergence of drug-resistant strains of Mtb has prompted a search for antimycobacterial agents. Several phenothiazines analogs are highly tuberculocidal in vitro, suppress Mtb growth in a mouse model of acute infection, and represent lead compounds that may give rise to a class of selective antibiotics.
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Mycobacterium tuberculosis ͉ respiratory chain

T
he World Health Organization estimates that two billion people are infected with Mycobacterium tuberculosis (Mtb), and two million people die of the disease each year (1) . Most individuals infected with the organism are latent carriers who have a 2-23% lifetime risk of developing reactivation tuberculosis (TB). The risk dramatically increases if the carrier's immune system is suppressed. Also, drug resistance is a serious concern; the isoniazid (INH)-resistance rate is Ϸ10%, and the rifampicin (RIF) resistance rate is Ϸ1%, with lower numbers in countries with effective TB programs and higher numbers in countries with deficient TB programs. The World Health Organization declared TB infections to be a global public health emergency (1) , and the need to identify targets for antimicrobial therapy remains urgent.
Mtb is capable of establishing persistent infection in the host by using a complex interplay between the host immune system and bacterial survival mechanisms. In the persistent infection, Mtb adapt to depletion of available oxygen and nutrients and enter a stage of nonreplicating persistence (NRP) in granulomatous or necrotic lesions. NRP Mtb are resistant to INH, ethambutol, and RIF, but they become sensitive to metronidazole in vitro (2) . Given the critical role of oxygen in the generation of cellular energy and bacterial long-term survival, there is surprisingly little information on oxidative phosphorylation in Mtb. Clearly, oxidative phosphorylation is a central component in the production of ATP and the subsequent growth and pathogenesis of Mtb. Here, we characterize the aerobic respiratory pathway and show that NADH:menaquinone oxidoreductase (Ndh) is a key target for TB agents. Infectious Diseases Contract NO1-A1-75320. Cells (12 g of wet weight) were washed with 10 ml of phosphate-digitonin buffer (50 mM sodium phosphate, pH 7.4, containing 0.1% digitonin) and resuspended in the same buffer. The bacteria were lysed by passage through a French press at 14,000 kPa, and the suspension was centrifuged at 12,000 ϫ g for 15 min to remove cellular debris. The supernatant was further clarified by centrifugation at 50,000 ϫ g for 50 min. This supernatant was used as the membrane-containing fraction (or cell-free extract) for spectral studies. To isolate cell membranes, the 50,000 ϫ g supernatant was centrifuged at 150,000 ϫ g for 60 min. The resulting pellet was washed with phosphate-digitonin buffer, resuspended, and then centrifuged at 150,000 ϫ g for 60 min a second time. Protein concentrations were determined by bicinchoninic assay (BCA, Pierce) by using BSA as the standard. UV-visible spectra were recorded at room temperature on a Cary 4E dual-beam spectrophotometer (Varian) by using a scan speed of 120 nm͞min and a slit width of 1 nm. Reduction of 21.3 mg͞ml membrane protein was accomplished by a 3-min incubation with 5 mM NADH. To illustrate the spectral perturbation due to CO binding of terminal oxidases, CO gas was gently bubbled into the sample for 5 min before NADH reduction. For the samples containing trifluoperazine (TPZ), drug was added to the sample and incubated for 5 min before the addition of NADH.
Materials and Methods
Amperometric Assay. Oxygen consumption by respiration of Mtb cytoplasmic membranes was measured by a polarographic method. Mtb membranes (50 mg͞ml) were suspended in 0.1 M potassium phosphate buffer (pH 7.4), and 10 mM NADH was added to initiate the respiration. Subsequently, 1 mM TPZ or vehicle and then 10 mM sodium ascorbate plus 1 mM 3,3,5,5-tetramethylphenylenediamine (TMPD) were added into the reaction mixture, as shown in Fig. 2B .
NADH-Quinone Oxidoreductase Activity Assay. For the NADHquinone oxidoreductase activity assay of Mtb membrane, the membrane was dialyzed against 100 mM potassium phosphate buffer (pH 7.5) containing 1 mM EDTA at 4°C overnight to remove endogenous reducing substrates. The Mtb membrane (3 mg͞ml) was suspended in the phosphate buffer containing 10 mM KCN and 100 M menaquinone 1 (MK 1 ) or Q 1 . Drug or vehicle was added as desired, and the reaction mixture was incubated for 5 min at 30°C. The reaction was initiated by adding 100 M NADH, and the absorbance change at 340 nm was monitored by using a custom-built 1098 spectrophotometer (Hitachi, Tokyo). NADH oxidation did not occur in the absence of membrane protein or quinone. For the purified Ndh or NdhA, NADH-quinone oxidoreductase activity was measured in 50 mM sodium phosphate buffer (pH 7.0) containing 150 mM NaCl and 2% (wt͞vol) potassium cholate. The reaction mixture contained 50 M Q 2 ͞1 g of purified enzyme, and it was initiated by adding 100 M NADH and monitored by following the absorbance change at 340-400 nm with a PerkinElmer 557 double-beam dual-wavelength spectrophotometer at 37°C. For chlorpromazine (CPZ)-inhibition assays, Ϸ1 g of purified enzyme and 50 M Q 2 were incubated in the reaction mixture with various amounts of CPZ for 2-3 min at room temperature before the addition of NADH.
Expression and Purification of Mtb ndh and ndhA in Escherichia coli.
The Mtb ndh and ndhA genes were amplified by PCR using the Mtb genomic DNA and template, and the products were cloned in pET16b expression plasmid, which contains an N-terminal His-6-tag. Mtb Ndh and NdhA were reproducibly expressed in E. coli strain BL21(DE3), and the products were localized to the cytoplasmic membrane. The E. coli cell suspension in buffer A (50 mM Hepes, pH 7.0͞100 mM KCl͞1 mM PMSF) was passed through a French press twice at 14,000 kPa. Next, the suspension was centrifuged at 12,000 ϫ g for 15 min to remove unbroken cells and debris. The resulting supernatant was ultracentrifuged at 130,000 ϫ g for 30 min. The membrane pellet was resuspended in buffer A and ultracentrifuged at 130,000 ϫ g again for 15 min. The cytoplasmic membranes thus obtained were resuspended in buffer A, 2% (wt͞vol) sodium cholate (pH 7.2) was added, and the mixture was solubilized by incubation at 4°C for 1 h. The mixture was next ultracentrifuged at 130,000 ϫ g for 30 min, and solubilized proteins in the supernatant were collected. We added 1 ml of buffer A-equilibrated Talon (BD Biosciences) resin, and the mixture was incubated at 4°C for 1 h. The resin was transferred into a column was washed with 30 ml of buffer A with 1% cholate, followed by 50 ml of buffer A with 1% cholate and 10 mM imidazole. Last, the bound proteins were eluted with buffer A with 1% cholate and 100 mM imidazole. Purified recombinant Mtb Ndh and NdhA were used immediately for activity assays.
Determination of the Minimum Inhibitory Concentration (MIC) by the
Bactec MGIT 960. The MIC for each compound was determined by the Bactec MGIT (mycobacteria growth indicator tube) 960 system. Mtb H 37 R v was grown in Middlebrook 7H9 broth until the growth index (GI) reached 75 (GI is a scale in the Bactec system (Becton Dickinson), which ref lects the amount of growth) and was then diluted 2,500-fold and used as the inocula. The vials were dispensed with different dilutions of drug to reach final concentrations ranging 0.2-26 g͞ml. All of the drugcontaining vials were inoculated with 0.5 ml of the bacterial suspensions prepared as described above. Six drug-free controls were included with each test; three were inoculated with 0.5 ml of the suspension, and the remaining three were inoculated with 0.5 ml of a 1:100 dilution of the suspension. The vials were incubated at 37°C and read in a Bactec 960 reader every day until the GI in the control diluted 1:100 reached 75, with an increase in the GI of at least 10 for 3 consecutive days. The time to positive was 10 days for the undiluted control. MIC was defined as the lowest concentration of the drug that caused an increase in the GI equal to or less than the increase in the GI of the control diluted 1:100.
Animal Studies: Test of Phenothiazine Efficacy in a BALB͞c Mouse
Model of Acute Mtb Infection. Each treatment group consisted of five female mice intranasally infected with 10 2 colony-forming units (cfu) of H37Rv Mtb on day 0. INH, RIF, or compound 1 was given orally on days 1-11. After 11 days of the indicated treatment, mice were killed, and the lungs and spleens were aseptically collected. Serial 10-fold dilutions were prepared of tissue homogenates in 7H9 media and were plated on 7H11 agar at 37°C for cfu enumeration after 4 weeks of incubation.
Results
Genetic Characterization of Aerobic Respiration in Mtb.
By analyzing the Mtb genome (3), we found the presence of a respiratory chain (RC) with a quinol oxidase branch and a cytochrome oxidase branch (Fig. 1) . Cytochrome bd oxidase is a quinol oxidase encoded by cydABCD, and cytochrome aa 3 is a cytochrome c oxidase encoded by ctaBCDE. We recently demonstrated (4) that the d-type oxidase is induced in mycobacteria under low-oxygen conditions and is important for microaerobic growth.
By homology, the aa 3 -type oxidase belongs to the hemecopper oxidase superfamily of respiratory oxidases critical for exponential growth under oxygen-rich conditions (5) . Mtb membrane preparations readily oxidize reduced bovine and yeast cytochromes c, yet extraction of Mtb membranes under high salt conditions failed to release free cytochrome c (data not shown). The quinone pool in Mtb is reduced by succinate:menaquinone oxidoreductase, which is comprised of four subunits, encoded by sdhABCD (complex II) and Ndh. We identified two types of Ndh in the Mtb genome (Fig. 1) . NDH-1 is a 14-subunit (nuoABCDEFGHIJKLMN) complex that is generally coupled to proton translocation. NDH-2, is an alternative, nonproton pumping, single-subunit oxidoreductase present in two copies (ndh and ndhA). The type II NADH:menaquinone oxidoreducatases, Ndh and NdhA, share 67% sequence identity, and their genes are separated by 17 kb. Other mycobacterial species, such as Mycobacterium leprae and M. smegmatis contain single copies of the ndh gene with 91% and 83% identical residues, respectively, compared with Mtb ndh. Furthermore, M. leprae depends solely on Ndh activity, as evidenced by the loss of all type I genes during the course of evolution except for a nuoN pseudogene. Inactivating mutations in M. smegmatis ndh lead to a thermosensitive lethal and auxotrophic phenotype (7) . In E. coli, type II NADH dehydrogenase is dominant under conditions of aerobic growth, whereas type I NADH dehydrogenase is induced under anaerobic conditions (8) (9) (10) (11) . Therefore, type II NADH dehydrogenase is an important respiratory enzyme for growth of Mtb in an aerobic environment.
Spectroscopic Characterization of Cytochrome Components. To characterize the cytochromes corresponding to the bc 1 complex and terminal oxidases of Mtb, we collected reduced minus oxidized difference spectra ( Fig. 2A) of Mtb membrane particles. Peaks were observed at 563, 532, and 430 nm, which are characteristic of the b-type cytochromes (12) . Peaks at 552 and 522 nm, which are typical of cytochrome c of the bc 1 complex, were also visible. A broad peak at 600 nm with a resonance peak at 444 nm presumably corresponded to cytochrome aa 3 . The bacilli were grown under fully aerobic conditions, making the discrete bd oxidase peak at 632 nm difficult to discern (4) . CO binds to terminal oxidases and causes a shift in heme absorbance. To confirm that the peak at 600 nm represented a terminal oxidase, [NADH-reduced plus CO] minus [NADH-reduced] spectra were obtained (Fig. 2B) . CO binding produced a trough at 444 nm and a peak at 429 nm. The cytochrome c peak of the bc 1 complex at 552 nm was not visible in the [NADH-reduced plus CO] minus [NADH-reduced] difference spectrum, consistent with a cytochrome that does not bind oxygen.
Determination of the Mechanism of Action of Phenothiazines.
The steady-state rate of respiration of Mtb membrane particles was determined in a cell-free amperometric assay. Addition of NADH to Mtb membrane particles resulted in an immediate linear consumption of oxygen, but consumption was fully inhibited by the addition of the phenothiazine TPZ (1 mM) (Fig. 3) . Respiration in the drug-arrested membranes was restored by the addition of 10 mM ascorbate and 1 mM TMPD, which donate electrons at the level of cytochrome c (Fig. 4A) . Thus, the phenothiazine affected both respiratory branches in Mtb. The recovery of oxygen consumption implied that the site of inhibition by TPZ is upstream of cytochrome c. To confirm this site of action, we tested the ability of TPZ to inhibit the reduction of bovine cytochrome c. By using the 550-to 540-nm wavelength pair, we determined that TPZ (100 M) inhibited the rate of reduction of cytochrome c by 75%.
To determine whether this block affected bd oxidase or the bc 1 complex, we collected [NADH-reduced] minus [airoxidized] difference spectra in the presence of TPZ (Fig. 4B) . After incubation with 100 M TPZ, the peaks corresponding to cytochromes b, c, a, and d not only failed to increase but were oxidized below baseline. Thus, phenothiazines inhibit electron transport in Mtb at a point before the reduction of cytochrome c.
To test whether phenothiazines inhibited Ndh activity, the electron-transport chain was blocked with 10 mM KCN, and the rate of oxidation of NADH in the presence of menaquinone 1 (MK 1 ) was measured. The addition of compound 1 resulted in a concentration-dependent decrease in Ndh activity with an IC 50 of 158 M. Flavone, a weak inhibitor of type II NADH dehydrogenase, suppressed NADH oxidation with an IC 50 of 750 M. Classic inhibitors of type I NADH dehydrogenase, such as rotenone (10 M), piericidin A (10 M), and pyridaben (10 M) did not inhibit Mtb Ndh activity. Also, deamino-NADH, a type I NADH dehydrogenase specific substrate, was not oxidized by Mtb membranes. Therefore, type II NADH dehydrogenase is a specific target site of phenothiazines.
Next, we tested whether phenothiazines inhibited succinate dehydrogenase activity (complex II). In this assay, the dye dichlorophenolindophenol was used as an electron acceptor and succinate as the electron donor. Phenothiazine concentrations as high as 400 M did not inhibit the reduction of dye. These results were confirmed by using the amperometric assay with succinate as the electron donor. The rate of oxygen consumption in this assay was not altered by the phenothiazines. This result further confirms that the inhibitory activity of phenothiazines is specific for type II NADH dehydrogenase.
Phenothiazines Inhibit Recombinant Ndh and NdhA. As described above, Mtb contains two copies of type II NADH dehydrogenase genes, ndh and ndhA. To determine whether Ndh or NdhA are specific targets for phenothiazine action, we cloned and independently expressed each of the genes in E. coli with N-terminal His-6-tags. The recombinant proteins were purified by affinity chromatography, and anti-His-6 Western blotting indicated single bands of 51 kDa (Fig. 5A) , consistent with the expression of Ndh and NdhA gene products. The recombinant proteins were capable of oxidizing NADH in the presence of ubiquinone 2. Next, a titration of the NADH:unquinone 2 oxidoreductase activity with CPZ demonstrated an IC 50 of Ϸ10 M for both Ndh and NdhA enzymes (Fig. 5B) . Therefore, both Ndh and NdhA are inhibited by the action of phenothiazines.
Screening Phenothiazine Analogs. To investigate this class of drugs further, a series of phenothiazines were tested in an Mtb growthinhibition assay. We screened 50 phenothiazine analogs (GlaxoSmithKline, Collegeville, PA) for inhibition of Mtb growth. The MIC for each compound was determined by using the Bactec MGIT 960 system. The MICs of compound 1 (1.11 g͞ml), compound 2 (3.44 g͞ml), compound 3 (3.96 g͞ml), TPZ (19.2 g͞ml), CPZ (9.23 g͞ml), RIF (0.5 g͞ml), and INH (0.15 g͞ml) were determined by using the Bactec 960 system. The bacteriocidal effect of these drugs was demonstrated by the failure to recover colonies on plates from cultures at 35 days. The convincing antimycobacterial activity of phenothiazine compounds in our earlier studies led us to test whether the compounds were effective in a more clinically relevant mouse model of acute infection. We tested compound 1 for in vivo activity against H37Rv Mtb in female BALB͞c mice (Fig. 6 ).
Mice were initially intranasally infected with Mtb on day 0 and then given INH, RIF, or compound 1 orally on days 1-11. Mice were then killed, and the levels of Mtb in the lung and spleen were determined. Animals receiving 100 mg͞kg compound 1 showed a statistically significant 90% decrease in cfu in the lung, compared with animals receiving vehicle. Animals treated with compound 1 showed no cfu in the spleen, whereas three of five animals receiving vehicle alone had recoverable organisms.
Discussion
The type II NADH dehydrogenase is a unique and important antimicrobial target. Human mitochondria use only type I NADH dehydrogenase, whereas Mtb contains both type I and type II NADH dehydrogenases. It is not known whether the Mtb NDH-1 genes are expressed in any growth conditions. DNAarray analysis revealed that the level of transcription of Mtb NDH-1 is down-regulated upon starvation in vitro (14) , but transposon insertions apparently are tolerated in the nuoAϳN gene cluster, suggesting that NDH-1 is dispensable for growth in vitro (15) . In the case of E. coli, type II NADH dehydrogenase is dominantly expressed under aerobic growth conditions, whereas type I NADH dehydrogenase is induced under semiaerobic conditions (8, 10, 11) . Recent studies (16) showed that the knockout of ndhA is possible in Mtb, and the lack of a viable strain containing an insertionally inactivated ndh suggests that it is a lethal phenotype. Furthermore, M. leprae depends solely on Ndh activity as evidenced by the loss of all type I genes except a nuoN pseudogene during the course of evolution (3). Inactivating mutations in M. smegmatis ndh lead to a thermosensitive lethal and auxotrophic phenotype (7) . Therefore, it is reasonable to suggest that type II NADH dehydrogenase is the sole NADH dehydrogenase enzyme in the Mtb RC for growth in an aerobic environment. The antimycobacterial activity of these phenothiazines has been sporadically reported over the past 40 years (17) (18) (19) . The efficacy of phenothiazines as antitubercular drugs has not been investigated thoroughly, and the target sites of phenothiazines have remained unknown. Previous investigations suggested that phenothazines affect multiple sites of action in Mtb, including synthesis of lipids, proteins, and DNA. Of particular interest is an observation that TPZ exhibited a significant effect on in vitro ATP synthesis by M. leprae (20) . Cellular ATP level of M. leprae was dramatically reduced in the presence of 5 g͞ml TPZ in the growth media, suggesting that one of the target sites is the electron transport pathway. This prompted us to test whether these compounds were able to suppress Mtb growth in vivo and to identify type II NADH dehydrogenase as a target site of phenothiazines in the Mtb oxidative phosphorylation system.
In agreement with the literature, our data indicate that phenothiazines are potent inhibitors of Mtb growth in vitro. Phenothiazines exert significant tuberculocidal activity against Mtb strains resistant to INH, rifampin, streptomycin, pyrazinamide, and ethambutol combined (21, 22) . TPZ is effective against virulent Mtb strain H 37 R v in a macrophage model of infection, and it is reported as synergistic with both INH and RIF (23, 24) . Because the in vitro concentration required for bacteriocidal activity is Ͼ100-fold greater than the clinical concentration of drug in vivo (24), we endeavored to find analogs with greater potency. Our data indicate that compound 1 is 12-fold more potent than TPZ in the Bactec 960 growth assay. Phenothiazines are reported to be concentrated within macrophages, which may reduce the required dose for treatment significantly (21) . In contrast to TPZ, compound 1 is water soluble at pH 7.4, and initial cellular-toxicity studies of this compound in A-537 fibroblasts indicate an LD 50 of Ͼ28 g͞ml (data not shown). In our mouse model of acute infection, a 100 mg͞kg dose of compound 1 produced a 1-log decrease in cfu within the lung. Therefore, compound 1 is an important lead compound for the development of antitubercular drugs.
It is reasonable to speculate that the modulation of electron transport in mycobacteria by phenothiazines may have a profound effect on the entrance and maintenance of dormancy. Recently, the DosS͞DosT, Dos R (Rv3132c͞Rv2027c Rv3133c) system has been described, which is an oxygen-and NO-regulated, two-component system in Mtb, composed of two histidine kinases (DosS and DosT) and the responseregulator DosR (25, 26) . The Dos system has been implicated in the ability of mycobacteria to adapt to hypoxic environmental conditions (27, 28) . During a hypoxic exposure, the quinone pool shifts to a reduced state because of the absence of oxygen as an electron acceptor. Voskuil et al. (29) observed that CN reverses the NO induction of the Dos regulon and suggested that the Dos response could be mediated by cytochrome aa 3 . This suggestion is consistent with the recent results of Boshoff et al., who demonstrated that CN does not up-regulate the Dos regulon (30) . A drug such as phenothiazine, which is capable of blocking electron f low to menaquinone, would presumably result in an increase in the oxidized state of the entire RC, and thereby, it would prevent the organism from entering a Dos-mediated state. As a result, when the RC is clamped in the oxidized state, the bacteria behave in the short term as if they were under aerobic conditions, even if oxygen is limiting. In fact, CPZ treated bacteria show more robust short-term growth than bacteria not treated with CPZ under low-oxygen conditions (H.R. and E.A.W., unpublished data). Phenothiazines may accelerate the course of TB treatment by interfering with bacterial persistence, thus making other anti-TB agents more effective. 
